Rationale: TCR-T cell therapy plays a critical role in the treatment of malignant cancers. However, it is unclear how cells are affected by PD-L1 molecule tumor environment. We performed an in-depth evaluation on differential expressions can affect functionality T cells. Methods: used MART-1-specific (TCR-TMART-1), stimulated with MART-127-35 peptide-loaded MEL-526 cells, expressing different p...

Both the programmed death (PD) 1-PD-ligand (PD-L) pathway and regulatory T (T reg) cells are instrumental to the maintenance of peripheral tolerance. We demonstrate that PD-L1 has a pivotal role in regulating induced T reg (iT reg) cell development and sustaining iT reg cell function. PD-L1(-/-) antigen-presenting cells minimally convert naive CD4 T cells to iT reg cells, showing the essential ...

Tumor cells are capable of limiting antitumor CD8+ T cell responses through their cell surface expression of PD-L1. In addition to PD-1 expressed by CD8+ T cells, PD-L1 also binds to CD80 expressed by CD8+ T cells. The influence of the PD-L1/CD80 interaction on CD8+ T cell function has not been fully characterized, so we sought to investigate the impact of the PD-L1/CD80 interaction on PD-L1-in...

Background: Targeting the PD-1/PD-L1/L2 pathway combined with other immunosuppressive signaling, such as CD73/A2aR adenosine has emerged a promising strategy for cancer treatment. The genetic characteristics of these immune checkpoints need to be further investigated in diffuse large B-cell lymphoma (DLBCL). Methods: We performed whole-exome sequencing/targeted deep sequencing investigate and C...

L1-CAM (L1 cell-adhesion molecule), or more simply L1, plays an important role in the progression of human carcinoma. Overexpression promotes tumour-cell invasion and motility, growth in nude mice and tumour metastasis. It is feasible that L1-dependent signalling contributes to these effects. However, little is known about its mechanism in tumour cells. We reported previously that L1 is cleaved...

Abstract PD-L1/PD-1 receptor pathway represents an important way of cancer cells to escape immune surveillance, yet only small portions patients can benefit from PD-1/PD-L1 inhibitors. This is at least partially due incomplete understanding biology in cancer. Although the interaction extracellular domains between PD-L1 and PD-1 on well studied, function inside cells, however, has not been estab...

3T3-L1 cells have been used as a model to study the differentiation and physiology of adipocytes. Exogenous expression of proteins in these cells offers the prospect of understanding the protein's function(s) in adipose tissue. Viral vectors, in particular, adenovirus, have proven to be a powerful means for introduction of genes into many cell types. However, we have previously shown that 3T3-L...

BACKGROUND Tumor cells express programmed death ligand 1 (PD-L1) and is a key immune evasion mechanism. PD-L1 expression in multiple breast cancer cell lines was evaluated to identify intrinsic differences that affect their potential for immune evasion. METHODS PD-L1 expression was analyzed in six breast cancer cell lines: AU565&MCF7 (luminal), BT20&HCC1143 (basal A), MDA231&HCC38 (basal B). ...

Abstract
 Background: Immune biologic markers that can predict clinical response to anti-PD-1/PD-L1 therapy are needed identify and validate tumor immunotherapy studies. High PD-L1 expression is associated with increased in patients various types of cancer treated inhibitors the PD-1/PD-L1 pathway. The researcher wanted see clinicopathological characteristics invasive breast carcinoma acco...